{
    "clinical_study": {
        "@rank": "55431", 
        "arm_group": {
            "arm_group_label": "Aurora Treatment Arm", 
            "arm_group_type": "Experimental", 
            "description": "Endometrial Ablation"
        }, 
        "brief_summary": {
            "textblock": "The primary objective of this study is to evaluate the use of the Aurora Ablation System in\n      reducing menstrual blood loss at 12 months post-treatment.  The occurrence of adverse events\n      will be assessed along with an assessment of the reduction of uterine bleeding as measured\n      by a pictorial blood loss assessment chart (PBLAC) or menstrual diary."
        }, 
        "brief_title": "A Two-Phase Clinical Study of the Minerva AURORA Ablation System", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Menorrhagia Due to Benign Causes", 
        "condition_browse": {
            "mesh_term": "Menorrhagia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Refractory menorrhagia with no definable organic cause (abnormal uterine bleeding)\n\n          2. Female subject from age 35 to 50 years\n\n          3. Uterine sound measurement of 6.0cm to 10.0cm (external os to internal fundus)\n\n          4. A minimum PBLAC score of >150 for 3 months prior to study enrollment; OR, A minimum\n             PBLAC score >150 for one month for women who either\n\n               1. had at least 3 prior months documented failed medical therapy; or\n\n               2. had a contraindication to medical therapy; or\n\n               3. refused medical therapy\n\n          5. Premenopausal at enrollment as determined by FSH measurement \u2264 40 IU/ml\n\n          6. Not pregnant and no desire to conceive at any time\n\n          7. Patient agrees not to use hormonal contraception or any other medical intervention\n             for bleeding during the study\n\n          8. Able to provide written informed consent using a form that has been approved by the\n             reviewing IRB/EC\n\n          9. Subject agrees to follow-up exams and data collection, including ability to\n             accurately use menstrual diaries\n\n         10. Subject who is literate or demonstrates an understanding on how to use menstrual\n             diaries\n\n        Exclusion Criteria:\n\n          1. Pregnancy or subject with a desire to conceive\n\n          2. Complex endometrial hyperplasia as confirmed by histology\n\n          3. Presence of active endometritis\n\n          4. Active pelvic inflammatory disease\n\n          5. Active sexually transmitted disease (STD)\n\n          6. Presence of bacteremia, sepsis, or other active systemic infection\n\n          7. Active infection of the genitals, vagina, cervix, uterus or urinary tract at the time\n             of the procedure\n\n          8. Known/suspected gynecological malignancy within the past 5 years\n\n          9. Known clotting defects or bleeding disorders\n\n         10. Untreated/unevaluated cervical dysplasia\n\n         11. Known/suspected abdominal/pelvic cancer\n\n         12. Prior uterine surgery (except low segment cesarean section) that interrupts the\n             integrity of the uterine wall (e.g., transmural myomectomy or classical cesarean\n             section)\n\n         13. Previous endometrial ablation procedure\n\n         14. Currently on medications that could thin the myometrial muscle, such as long-term\n             steroid use\n\n         15. Currently on anticoagulants\n\n         16. Abnormal or obstructed cavity as confirmed by hysteroscopy or SIS, specifically:\n\n               1. Septate or bicornuate uterus or other congenital malformation of the uterine\n                  cavity\n\n               2. Pedunculated or submucosal myomas distorting the uterine cavity\n\n               3. Polyps likely to be the cause of the subject's menorrhagia\n\n               4. Intramural or subserosal myomas that distort the uterine cavity\n\n         17. Presence of an intrauterine device (IUD)\n\n         18. Subject currently on hormonal birth control therapy or unwilling to use a\n             non-hormonal birth control post-ablation.\n\n         19. Any general health condition which, in the opinion of the Investigator, could\n             represent an increased risk for the subject\n\n         20. Any subject who is participating in any other research of an investigational drug or\n             device that has not yet completed the primary endpoint evaluation."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "23", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02035332", 
            "org_study_id": "CIP0001"
        }, 
        "intervention": {
            "arm_group_label": "Aurora Treatment Arm", 
            "description": "Ablation of the endometrial lining of the uterus using the Aurora System", 
            "intervention_name": "Aurora Endometrial Ablation System", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Excessive Uterine Bleeding", 
            "Menorrhagia", 
            "Endometrial Ablation"
        ], 
        "lastchanged_date": "January 10, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Szeged", 
                        "country": "Hungary", 
                        "state": "Csongrad", 
                        "zip": "6725"
                    }, 
                    "name": "University of Szeged"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Debrecen", 
                        "country": "Hungary", 
                        "state": "Hajd\u00fa-Bihar", 
                        "zip": "4043"
                    }, 
                    "name": "Ken\u00e9zy Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Budapest", 
                        "country": "Hungary", 
                        "zip": "1115"
                    }, 
                    "name": "Szt Imre Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "Hungary"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Two-Phase Clinical Study of the Minerva AURORA Ablation System", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Hungary: Scientific and Medical Research Council Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Uterine bleeding as measured by a pictorial blood loss assessment chart (PBLAC) or menstrual diary.", 
                "measure": "Uterine Bleeding", 
                "safety_issue": "No", 
                "time_frame": "12 Months"
            }, 
            {
                "description": "The primary safety endpoint is the occurrence of adverse events.", 
                "measure": "Occurrence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02035332"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Subject satisfaction and response to subject questionnaires.", 
            "measure": "Long-Term Subject Follow-up", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "source": "Minerva Surgical, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Minerva Surgical, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2011", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}